Abstract 718O
Background
PTEN loss, which leads to elevated PI3K/Akt pathway activation, is one of the most common changes in mCRPC and is associated with a worse prognosis. Ipatasertib (Ipat) is a potent, novel oral ATP-competitive inhibitor of Akt. When combined with abiraterone acetate (Abi), Ipat improved radiographic progression-free survival (rPFS) and overall survival in unselected patients (pts) with mCRPC (de Bono et al, ASCO 2016). In this analysis, rPFS in pts with PTEN loss was assessed, and the relationship between PTEN expression by immunohistochemistry (IHC) and genomic loss of PTEN was further explored.
Methods
Pts with mCRPC, previously treated with docetaxel, were randomized 1:1:1 (double blinded) to 3 arms: Ipat-400 mg, Ipat-200 mg or placebo (Pbo) in combination with Abi 1000 mg and prednisone 10 mg daily. PTEN expression was assessed by IHC in archival or fresh tumor samples, with prospectively defined criteria for PTEN loss. PTEN genomic loss was detected by fluorescence in situ hybridization (FISH) and next-generation sequencing (NGS).
Results
253 pts were randomized and 173 rPFS events (68%) were observed at the primary analysis. PTEN status was IHC evaluable in 165 cases, with PTEN loss reported in 71 cases (43%). PTEN loss was associated with a worse rPFS outcome in the Pbo arm, while Ipat improved rPFS compared with Pbo at both doses, with a greater treatment effect at 400 mg and in PTEN-loss cancers (Table). There was high concordance for PTEN loss between FISH, NGS and IHC.
| PTEN Loss | Non-PTEN Loss | |||||
|---|---|---|---|---|---|---|
| Ipat-400 + Abi (n = 25) | Ipat-200 + Abi (n =25) | Pbo + Abi (n =21) | Ipat-400 + Abi (n = 32) | Ipat-200 + Abi (n = 27) | Pbo + Abi (n = 35) | |
| rPFS events, n % | 15 (60) | 16 (64) | 18 (86) | 20 (63) | 20 (74) | 26 (74) |
| Median, months | 11.5 | 11.1 | 4.6 | 7.5 | 4.6 | 5.6 |
| Unstratified HR | 0.39 | 0.46 | 0.84 | 1.13 | ||
| 90% CI | 0.22-0.70 | 0.25-0.83 | 0.51-1.37 | 0.69-1.85 | ||
| P value | 0.0064 | 0.0285 | 0.5647 | 0.6762 | ||
Conclusions
This study indicates that combining Akt inhibition with improved AR pathway blockade in mCRPC may provide pt benefit and is the first clinical demonstration supporting PTEN loss as a predictive response biomarker for mCRPC. These findings warrant the co-development of Ipat with a companion diagnostic assay to select mCRPC pts with PTEN loss and improve outcomes. NCT01485861.
Clinical trial identification
NCT01485861
Legal entity responsible for the study
F. Hoffmann La-Roche
Funding
F. Hoffmann La-Roche
Disclosure
J.S. de Bono: Genentech Advisory Board meetings as a paid consultant. C. Massard: Genentech, Astellas, Medimmune, Ipsen, Jansen, Novartis, Pfizer, Roche, Sanofi, Orion, New Oncology.
S. Bracarda: Advisory Board Member for: Bayer, Pfizer, Astellas, BMS, Novartis, Exelixis, Roche. Honoraria: Pfizer, Novartis, Astellas, Bayer, BMS. W. Yu, W. Chan, S. Gendreau, L. Zhang, M.J. Wongchenko, D. Maslyar: Employee and shareholder of Genentech/Roche.
All other authors have declared no conflicts of interest.
Resources from the same session
Risk of prostate cancer mortality in men with an initial benign needle core biopsy set: a population based analysis with up to 20 years of follow-up
Presenter: Nina Klemann
Session: Genitourinary tumours, prostate
Resources:
Abstract
PROSELICA: Health-related quality of life (HRQL) and post-hoc analyses for the phase 3 study assessing cabazitaxel 20 (C20) vs 25 (C25) mg/m2 post-docetaxel (D) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Johann de Bono
Session: Genitourinary tumours, prostate
Resources:
Abstract
Prediction of PARP inhibitor response and resistance utilizing a CTC phenotypic classifer in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results from the NCI 9012 trial
Presenter: Felix Feng
Session: Genitourinary tumours, prostate
Resources:
Abstract
Pembrolizumab for patients with advanced prostate adenocarcinoma: Preliminary results from the KEYNOTE-028 study
Presenter: Aaron Hansen
Session: Genitourinary tumours, prostate
Resources:
Abstract
Modelling relapse in patients with high-risk localised prostate cancer treated randomly in the GETUG 12 phase III trial reveals two populations of relapsing patients
Presenter: Cécile Vicier
Session: Genitourinary tumours, prostate
Resources:
Abstract
Metastasis free survival (MFS) is a surrogate for overall survival (OS) in localized prostate cancer (CaP)
Presenter: Wanling Xie
Session: Genitourinary tumours, prostate
Resources:
Abstract
Long term efficacy and QOL data of chemohormonal therapy (C-HT) in low and high volume hormone naïve metastatic prostate cancer (PrCa): E3805 CHAARTED trial
Presenter: Christopher Sweeney
Session: Genitourinary tumours, prostate
Resources:
Abstract
Invited discussant abstracts LBA29 and 719O
Presenter: Winald Gerritsen
Session: Genitourinary tumours, prostate
Resources:
Presentation
Invited discussant abstracts 725PD, 726PD, 727PD, 728PD, 729PD and 730PD
Presenter: David Olmos
Session: Genitourinary tumours, prostate
Resources:
Presentation
Webcast
Invited discussant abstracts 720PD, 721PD, 722PD, 723PD and 724PD
Presenter: Matthew Sydes
Session: Genitourinary tumours, prostate
Resources:
Presentation
Webcast